Jagiellonian University Repository

Elevated level of troponin but not N-Terminal probrain natriuretic peptide is associated with increased risk of sudden cardiac death in hypertrophic cardiomyopathy calculated according to the ESC guidelines 2014

pcg.skipToMenu

Elevated level of troponin but not N-Terminal probrain natriuretic peptide is associated with increased risk of sudden cardiac death in hypertrophic cardiomyopathy calculated according to the ESC guidelines 2014

Show full item record

dc.contributor.author Rajtar-Salwa, Renata pl
dc.contributor.author Petkow-Dimitrow, Paweł [SAP20001311] pl
dc.contributor.author Hładij Rafał pl
dc.date.accessioned 2020-01-17T09:20:34Z
dc.date.available 2020-01-17T09:20:34Z
dc.date.issued 2017 pl
dc.identifier.issn 0278-0240 pl
dc.identifier.uri https://ruj.uj.edu.pl/xmlui/handle/item/142490
dc.language eng pl
dc.rights Udzielam licencji. Uznanie autorstwa 4.0 Międzynarodowa *
dc.rights.uri http://creativecommons.org/licenses/by/4.0/pl/legalcode *
dc.title Elevated level of troponin but not N-Terminal probrain natriuretic peptide is associated with increased risk of sudden cardiac death in hypertrophic cardiomyopathy calculated according to the ESC guidelines 2014 pl
dc.type JournalArticle pl
dc.abstract.en The aim of this study was to assess the relationship between biomarkers (high-sensitive troponin I [hs-TnI], N-Terminal probrain natriuretic peptide [NT-proBNP]) and calculated 5-year percentage risk score of sudden cardiac death (SCD) in hypertrophic cardiomyopathy (HCM). Methods. In 46 HCM patients (mean age 39 ± 7 years, 24 males and 22 females), echocardiographic examination, including the stimulating maneuvers to provoke maximized LVOT gradient, had been performed and next ECG Holter was immediately started. After 24 hours, the ECG Holter was finished and the hs-TnI and NT-proBNP have been measured. Patients were divided according to 1/value of both biomarkers (hs-TnI-positive and hs-TnI-negative subgroups) and 2/(NT-proBNP lower and higher subgroup divided by median). Results. In comparison between 19 patients (hs-TnI positive) versus 27 patients (hs-TnI negative), the calculated 5-year percentage risk of SCD in HCM was significantly greater (6.38 ± 4.17% versus 3.81 ± 3.23%, P < 0 05). In comparison between higher NT-proBNP versus lower NT-proBNP subgroups, the calculated 5-year percentage risk of SCD in HCM was not significantly greater (5.18 ± 3.63% versus 4.14 ± 4.18%, P > 0 05). Conclusions. Patients with HCM and positive hs-TnI test have a higher risk of SCD estimated according to SCD calculator recommended by the ESC Guidelines 2014 than patients with negative hs-TnI test. pl
dc.description.volume 2017 pl
dc.description.points 25 pl
dc.identifier.doi 10.1155/2017/9417908 pl
dc.identifier.eissn 1875-8630 pl
dc.title.journal Disease Markers pl
dc.language.container eng pl
dc.affiliation Wydział Lekarski : Instytut Kardiologii pl
dc.subtype Article pl
dc.identifier.articleid 9417908 pl
dc.rights.original CC-BY; otwarte czasopismo; ostateczna wersja wydawcy; w momencie opublikowania; 0 pl
dc.identifier.project ROD UJ / OP pl
dc.cm.id 87504
dc.cm.date 2020-01-07
.pointsMNiSW [2017 A]: 25


Files in this item

This item appears in the following Collection(s)

Udzielam licencji. Uznanie autorstwa 4.0 Międzynarodowa Except where otherwise noted, this item's license is described as Udzielam licencji. Uznanie autorstwa 4.0 Międzynarodowa